SCHEMBL428515

SCHEMBL428515

O=C1CC2(CCCC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428337 0.97 ESR2 (0.38)
SCHEMBL136340 0.93
SCHEMBL664740 0.88 SMN1; SMN2 (0.34)
SCHEMBL22501957 0.86
SCHEMBL1177140 0.85 SMN1; SMN2 (0.33)
SCHEMBL486771 0.81 ESR2 (0.32)
SCHEMBL14441602 0.79 TRIM24 (0.33)
SCHEMBL2775918 0.79 TRIM24 (0.40)
SCHEMBL17452514 0.78
SCHEMBL3241777 0.77 TRIM24 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059906-A Compounds for inhibiting PTPN proteins and uses thereof 艾斯拓康生物医药(天津)有限公司 2026-05-19 CN disclosed
CN-122010871-A Compounds for inhibiting PTPN proteins and uses thereof 艾斯拓康生物医药(天津)有限公司 2026-05-12 CN disclosed
US-20250205244-A1 METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS 4E THERAPEUTICS, INC. 2025-06-26 US disclosed
US-20250186436-A1 SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE 4E THERAPEUTICS, INC. 2025-06-12 US disclosed
US-20250179065-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2025-06-05 US disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
EP-4380566-A1 METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS 4E Therapeutics, Inc. (US) 2024-06-12 EP disclosed
CN-112778311-B Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-06-04 CN disclosed
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2024-05-30 US disclosed
CN-118076354-A Methods of treating migraine with MNK inhibitors 4E治疗公司 2024-05-24 CN disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
US-7439263-B2 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2008-10-21 US disclosed
EP-1598350-B1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis SERVIER LAB (FR) 2007-07-11 EP disclosed
US-20050261501-A1 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2005-11-24 US disclosed
EP-1598350-A1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis LES LABORATOIRES SERVIER (FR) 2005-11-23 EP disclosed